Adult respiratory distress syndrome: Do selective anticoagulants help?

American Journal of Respiratory Medicine

Volumn 1, Issue 6, 2002, Pages 383-391

  Idell, Steven ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN III; BLEOMYCIN; DROTRECOGIN; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO; PLASMIN; PLASMINOGEN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; STREPTOKINASE; TETRACYCLINE; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; FIBRIN DEPOSITION; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; INFLAMMATION; LUNG BLOOD VESSEL; LUNG FIBROSIS; LUNG INJURY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; THROMBOSIS;

EID: 0042355726     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03257165     Document Type: Review

References (75)

1. Idell S. Anticoagulants for ARDS: can they work? Am J Respir Crit Care Med 2001; 164: 517-20
2. Idell S. Coagulation, fibrinolysis and fibrin deposition in lung injury and repair. In: Lenfant C, Phan SH, Thrall RS, editors. Pulmonary fibrosis: lung biology in health and disease. New York: Marcel Dekker, 1995: 743-76
3. Gunther A, Siebert C, Scmidt R, et al. Surfactant alterations in severe pneumonia, ARDS and cardiogenic lung edema. Am J Resp Crit Care Med 1996; 153: 176-84
4. Gunther A, Kalinowski M, Rousseau S, et al. Surfactant incorporation markedly alters mechanical properties of a fibrin clot. Am J Respir Cell Mol Biol 1995; 13: 712-8
5. Idell S. Extravascular coagulation and fibrin deposition in acute lung injury. New Horizons 1994; 2: 566-74
6. Marshall R, Bellingan G, Laurent G. The acute respiratory distress syndrome: fibrosis in the fast lane. Thorax 1998; 53: 815-7
7. Idell S. The fibrinolytic defect in ARDS: a therapeutic opportunity? Clin Pulm Med 2002; 9: 13-9
8. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9
9. Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1983; 2: 41-73
10. Dvorak HF, Senger DR, Dvorak AM, et al. Regulation of extravascular coagulation by microvascular permeability. Science 1985; 227: 1059-61
11. Rao LVM, Pendurhi UR. Factor VIIa-induced gene expression: potential implications in pathophysiology. Trends Cardiovasc Med 2001; 11: 14-21
12. Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 1982 Jan; 3: 35-56
13. Idell S, Peters J, James KK, et al. Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage. J Clin Invest 1989; 84: 181-93
14. Idell S, James KK, Gillies C, et al. Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition. Am J Pathol 1989; 135: 387-99
15. Idell S, James KK, Coalson JJ. Fibrinolytic activity in bronchoalveolar lavage of baboons with diffuse alveolar damage: trends in two forms of lung injury. Crit Care Med 1992; 20: 1431-40
16. Idell S, Peterson BT, Gonzalez KK, et al. Local abnormalities of coagulation and fibrinolysis and alveolar fibrin deposition in sheep with oleic acid-induced lung injury. Am Rev Resp Dis 1988; 138: 1282-94
17. Idell S, Gonzalez KK, MacArthur CK, et al. Bronchoalveolar lavage procoagulant activity in bleomycin-induced lung injury in marmosets: characterization and relationship to fibrin deposition and fibrosis. Am Rev Resp Dis 1987; 136: 124-33
18. Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232-7
19. Barazzone C, Belin D, Piguet P-F, et al. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J Clin Invest 1996; 98: 2666-73
20. Idell S, James KK, Levin EG, et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84: 695-705
21. Gunther A, Mosavi P, Heinemann S, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia: comparison with the acute respiratory distress syndrome. Am J Resp Crit Care Med 2000; 161: 454-62
22. Idell S, Koenig KB, Fair DS, et al. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991; 261: L240-8
23. Drake TA, Morissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: implication for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-97
24. McGee M, Rothberger H. Tissue factor in bronchalveolar lavage fluids: evidence for an alveolar macrophage source. Am Rev Respir Dis 1985; 131: 331-6
25. Chapman HA, Stahl M, Allen CL, et al. Regulation of the procoagulant activity within the bronchoalveolar compartment of normal human lung. Am Rev Resp Dis 1988; 137: 1417-25
26. Chapman HA, Bertozzi P, Reilly JJ. Role of enzymes mediating thrombosis and thrombolysis in lung disease. Chest 1988; 93: 1256-63
27. Tipping PG, Campbell DA, Boyce NW, et al. Alveolar macrophage procoagulant activity is increased in acute hyperoxic lung injury. Am J Pathol 1988; 131: 206-12
28. Idell S, Kumar A, Zwieb C, et al. Effects of TGF-beta and TNF-alpha on procoagulant and fibrinolytic pathways of human tracheal epithelial cells. Am J Physiol 1994; 267: L693-703
29. Idell S, Zwieb C, Boggaram J, et al. Mechanisms of fibrin formation and lysis by human lung fibroblasts: influence of TGF-beta and TNF-alpha. Am J Physiol 1992; 263: L487-94
30. Olman M, Mackman N, Gladson CL, et al. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1999; 96: 1621-30
31. Bertozzi P, Astedt B, Zenzius L, et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990 Mar 29; 322 (13): 890-7
32. Neuhof H, Seeger W, Wolf HRD. Generation of mediators by limited proteolysis during blood coagulation and fibrinolysis: its pathogenetic role in the adult respiratory distress syndrome (ARDS). Reseuscitation 1986; 14: 23-32
33. Nakstad B, Lyberg T, Skonsberg OH, et al. Local activation of the coagulation and fibrinolytic systems in lung disease. Thromb Res 1990; 57: 827-38
34. Zapol WM, Jones R. Vascular components of ARDS: clinical pulmonary hemodynamics and morphology. Am Rev Respir Dis 1987; 136: 471-4
35. Greene R. Pulmonary vascular obstruction in the adult respiratory distress syndrome. J Thorac Imaging 1986; 1: 31-8
36. Hasday JD, Bachwich PR, Lynch JP III, et al. Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis. Exp Lung Res 1988; 14: 261-78
37. Chapman HA, Allen CL, Stone OL. Abnormalities in pathways of fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis 1986; 133: 437-43
38. Kuhn C III, Boldt J, King TE, et al. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989; 140: 1693-703
39. Jackson LK. Idiopathic pulmonary fibrosis. Clin Chest Med 1982; 3: 579-92
40. Viscardi R, Broderick K, Sun CC, et al. Disordered pathways of fibrin turnover in lung lavage of premature infants with respiratory distress syndrome. Am Rev Respir Dis 1992; 146: 492-9
41. Idell S, Kumar A, Koenig KB, et al. Pathways of fibrin turnover in lavage of premature baboons with hyperoxic lung injury. Am J Respir Crit Care Med 1994; 149: 767-75
42. Sahn S. The pleura: state of the art. Am Rev Respir Dis 1988; 138: 184-234
43. Idell S, Pendurthi U, Pueblitz S, et al. Tissue factor pathway inhibitor in tetracycline-induced pleuritis in rabbits. Thromb Haemost 1998; 79: 649-55
44. Idell S, Girard W, Koenig KB, et al. Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 1991; 144: 187-94
45. Idell S, Zwieb C, Kumar A, et al. Pathways of fibrin turnover of human pleural mesothelial cells in vitro. Am J Respir Cell Mol Biol 1992; 7: 414-26
46. Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent and sanguinous pleural exudations. J Clin Invest 1949; 28: 173-90
47. Sahn SA. Use of fibrinolytic agents in the management of complicated parapneumonic effusions and empyemas. Thorax 1998 Aug; 53 Suppl. 2: S65-72
48. Light RW. Parapneumonic effusions: pleural diseases. 4th ed. Philadephia (PA): Lippincott Williams and Wilkins, 2001: 151-81
49. Colice GL, Curtis A, Deslauriers J, et al. Medical and surgical treatment of parapneumonic effusions: AACP consensus statement. Chest 2000; 18: 1158-71
50. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 2000; 22: 401-4
51. Vervloet MG, Thisj LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998; 24: 33-44
52. Ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000; 28: S9-S11
53. Saldeen T. The microembolism syndrome: a review. The microembolism syndrome. Stockholm: Almqvist and Wiskell, 1979: 7-44
54. Malik AB. Pulmonary microembolism. Physiol Rev 1983; 63: 1114-207
55. Kaplan JE, Malik AB. Thrombin-induced intravascular coagulation: role in vascular injury. Semin Thromb Hemost 1987; 13: 398-415
56. Johnson A, Tahamont MV, Malik AB. Thrombin-induced vascular injury. Am Rev Respir Dis 1983; 128: 38-44
57. Greene R, Lind S, Jantsch H, et al. Pulmonary vascular obstruction in severe ARDS: angiographic alterations after i.v. fibrinolytic therapy. Am J Roentgenol 1987; 148: 501-8
58. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92
59. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000; 28: S31-3
60. Bernard GR, Vincent J-L, Laterr P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709
61. Esmon CT. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 2000; 95: 1113-6
62. Forster A, Wells P. Tissue plasminogen activator for the treatment of deep venous thrombosis of the lower extremity: a systemic review. Chest 2001; 119: 572-9
63. Warren BI, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2002; 287: 1869-78
64. Chiron news. Chiron announces results of a phase III study of tifacogin in severe sepsis [online]. Available from URL: http://www.chiron.com/investor/index.htm [Accessed 2002 Mar 2]
65. de Jong E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-9
66. de Jong E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis 2001; 183: 1815-8
67. Welty-Wolf KE, Carraway MS, Huang YC-T, et al. Blockade of extrinsic coagulation decreases lung injury in baboons with gram negative sepsis. Am J Resp Crit Care Med 2001; 164: 1988-96
68. de Fouw NJ, de Jong YF, Haverkate F, et al. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor-no evidence for a cofactor role of protein S. Thromb Haemost 1988; 60: 328-33
69. Bajzar L, Neshelm ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 93-100
70. Brown LF, Dvorak AM, Dvorak HF. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and many other types of disease. Am Rev Respir Dis 1989; 140: 1104-7
71. Idell S. NHLBI workshop summary: fibrin turnover in lung inflammation and neoplasia. Am J Respir Crit Care Med 2001; 163: 1-7
72. Hardaway RM, Williams CH, Marvasti M, et al. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med 1990; 18: 1413-8
73. Ambrus JL, Ambrus CM. Changes in the fibrinolysin system in infantile and adult respiratory distress syndrome (ARDS), caused by trauma and/or septic shock in patients and in experimental animals. J Med 1990; 21: 67-84
74. Miazawa T, Tanemori N, Utsumi T, et al. Balloon occlusion pulmonary angiography and anticoagulant-antithrombotic therapy in ARDS-associated pulmonary vascular thrombosis. Nihon Kyobu Shikkan Gakki Zasshi 1991; 29: 439-43
75. Hardaway RM, Harke H, Williams CH. Fibrinolytic agents: a new approach in the treatment of adult respiratry distress syndrome. Adv Ther 1994; 11: 43-51